血液科指南

订阅

MedSci主页 / 所有栏目 / 血液科指南

2021 澳大利亚和新西兰成人免疫性血小板减少症管理共识指南

2021-10-10 澳大利亚和新西兰血栓形成和止血协会 MJA

免疫性血小板减少症髓系疾病

缺乏关于免疫性血小板减少性紫癜 (ITP) 基本临床困境的高质量证据强调了与当地治疗背景相关的当代指南的必要性。ITP 是通过排除诊断的，具有孤立性血小板减少症的标志性实验室发现。

中文标题：

2021 澳大利亚和新西兰成人免疫性血小板减少症管理共识指南

发布机构：

澳大利亚和新西兰血栓形成和止血协会

发布日期：

2021-10-10

简要介绍：

缺乏关于免疫性血小板减少性紫癜 (ITP) 基本临床困境的高质量证据强调了与当地治疗背景相关的当代指南的必要性。ITP 是通过排除诊断的，具有孤立性血小板减少症的标志性实验室发现。

相关资料下载：
[AttachmentFileName(sort=1, fileName=澳大利亚和新西兰成人免疫性血小板减少症管理共识指南.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2e3b11c0023a0411, title=2021 澳大利亚和新西兰成人免疫性血小板减少症管理共识指南, enTitle=, guiderFrom=MJA, authorId=0, author=, summary=缺乏关于免疫性血小板减少性紫癜 (ITP) 基本临床困境的高质量证据强调了与当地治疗背景相关的当代指南的必要性。ITP 是通过排除诊断的，具有孤立性血小板减少症的标志性实验室发现。, cover=https://img.medsci.cn/2022126/1643207746925_1608702.png, journalId=0, articlesId=null, associationId=2352, associationName=澳大利亚和新西兰血栓形成和止血协会 , associationIntro=澳大利亚和新西兰血栓形成和止血协会 (THANZ) , copyright=0, guiderPublishedTime=Sun Oct 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #1c1d1e;">缺乏关于免疫性血小板减少性紫癜 (ITP) 基本临床困境的高质量证据强调了与当地治疗背景相关的当代指南的必要性。</span><span style="color: #1c1d1e;">ITP 是通过排除诊断的，具有孤立性血小板减少症的标志性实验室发现。</span></p>, tagList=[TagDto(tagId=34037, tagName=免疫性血小板减少症), TagDto(tagId=117037, tagName=髓系疾病)], categoryList=[CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=9, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3513, appHits=68, showAppHits=0, pcHits=272, showPcHits=3444, likes=0, shares=4, comments=4, approvalStatus=1, publishedTime=Thu Jan 27 15:32:00 CST 2022, publishedTimeString=2021-10-10, pcVisible=1, appVisible=1, editorId=0, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Wed Jan 26 22:43:24 CST 2022, updatedBy=1608702, updatedName=dajiong, updatedTime=Fri Jan 05 18:35:51 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=澳大利亚和新西兰成人免疫性血小板减少症管理共识指南.pdf)])
澳大利亚和新西兰成人免疫性血小板减少症管理共识指南.pdf
下载请点击：
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1242134, encodeId=4557124213448, content=干活满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d118220881, createdName=ms4000000652979879, createdTime=Tue Aug 30 21:58:36 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194718, encodeId=df481194e18fb, content=好新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8904218583, createdName=13dc1c86m09暂无昵称, createdTime=Fri Feb 18 09:38:46 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194717, encodeId=84b91194e1750, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8904218583, createdName=13dc1c86m09暂无昵称, createdTime=Fri Feb 18 09:38:41 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
    2022-08-30 ms4000000652979879

    干活满满

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1242134, encodeId=4557124213448, content=干活满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d118220881, createdName=ms4000000652979879, createdTime=Tue Aug 30 21:58:36 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194718, encodeId=df481194e18fb, content=好新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8904218583, createdName=13dc1c86m09暂无昵称, createdTime=Fri Feb 18 09:38:46 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194717, encodeId=84b91194e1750, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8904218583, createdName=13dc1c86m09暂无昵称, createdTime=Fri Feb 18 09:38:41 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
    2022-02-18 13dc1c86m09暂无昵称

    好新

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1242134, encodeId=4557124213448, content=干活满满, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4d118220881, createdName=ms4000000652979879, createdTime=Tue Aug 30 21:58:36 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194718, encodeId=df481194e18fb, content=好新, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8904218583, createdName=13dc1c86m09暂无昵称, createdTime=Fri Feb 18 09:38:46 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194717, encodeId=84b91194e1750, content=干货, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f8904218583, createdName=13dc1c86m09暂无昵称, createdTime=Fri Feb 18 09:38:41 CST 2022, time=2022-02-18, status=1, ipAttribution=)]
    2022-02-18 13dc1c86m09暂无昵称

    干货

    0

相关指南

免疫性血小板减少症中的牙槽手术；系统评价和机构指南

巴西坎皮纳斯坎皮纳斯州立大学口腔医学门诊、血液学和血液治疗中心 · 2021-09-09

COVID-19 快速指南：疫苗引起的免疫性血小板减少症和血栓形成 (VITT)

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2021-07-29

2021 意大利共识建议：免疫性血小板减少症血小板生成受体激动剂的二线用药

国外血液科相关专家小组 · 2021-10-09

2019 ASH指南：免疫性血小板减少症

美国血液病学会(ASH,American Society of Hematology) · 2019-12-01